DLB Dolby Laboratories, Inc.
Patent Owners & Lessors · NYSE · SEC CIK 1308547 · Fiscal year ends 09/27
Financial factors as of 2026-06-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.6%
TTM net income YoY-14.4%
TTM EPS YoY-13.3%
Revenue 3-yr CAGR1.7%
Net income 3-yr CAGR1.0%
Margins
Gross margin87.6%
Operating margin17.7%
Net margin16.7%
FCF margin29.0%
EBITDA margin24.5%
Returns
ROE8.7%
ROA7.1%
ROIC (approx.)10.5%
Asset turnover0.43x
Leverage & solvency
Liabilities / assets17.9%
Debt / equity0.00x
Current ratio3.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.93x
Accruals ratio-6.7%
Payout ratio59.4%
Capex / revenue3.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-26 | FY20242024-09-27 | FY20232023-09-29 | FY20222022-09-30 | FY20212021-09-24 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.35B | $1.27B | $1.30B | $1.25B | $1.28B |
| Cost of revenue | $160.13M | $140.50M | $152.57M | $141.36M | $130.03M |
| Gross profit | $1.19B | $1.13B | $1.15B | $1.11B | $1.15B |
| R&D expense | $261.79M | $263.66M | $271.52M | $261.17M | $253.64M |
| SG&A expense | $286.53M | $270.39M | $258.48M | $275.31M | $224.16M |
| Operating income | $264.96M | $258.33M | $215.75M | $206.60M | $344.39M |
| Interest expense | — | — | — | $394,000 | $479,000 |
| Pretax income | $303.49M | $312.48M | $250.05M | $215.28M | $354.51M |
| Income tax | $46.99M | $48.16M | $48.41M | $31.38M | $36.69M |
| Net income | $255.02M | $261.82M | $200.66M | $184.09M | $310.23M |
| EBITDA | $352.79M | $333.88M | $298.31M | $295.07M | $440.25M |
| EPS (basic) | 2.66 | 2.74 | 2.10 | 1.84 | 3.07 |
| EPS (diluted) | 2.62 | 2.69 | 2.05 | 1.81 | 2.97 |
| Dividends declared per share | 1.32 | 1.23 | 1.11 | 1.02 | 0.91 |
| Weighted avg. shares (diluted) | 97.48M | 97.33M | 97.73M | 101.98M | 104.62M |
| Banking | |||||
| Net interest income | $15.38M | $34.08M | $28.09M | $6.17M | $3.01M |
| Balance sheet | |||||
| Cash & equivalents | $701.89M | $577.75M | $817.97M | $628.37M | $1.23B |
| Short-term investments | $703,000 | $0 | $139.15M | $189.21M | $38.84M |
| Receivables | $331.10M | $315.46M | $262.25M | $243.59M | $232.61M |
| Inventory | $30.42M | $33.73M | $35.62M | $23.55M | $10.96M |
| Current assets | $1.39B | $1.19B | $1.49B | $1.31B | $1.76B |
| PP&E, net | $470.61M | $479.11M | $481.58M | $513.48M | $534.38M |
| Goodwill | $529.90M | $533.21M | $408.41M | $365.15M | $340.69M |
| Intangibles | $397.06M | $434.51M | $167.43M | $112.27M | $122.89M |
| Total assets | $3.23B | $3.11B | $2.98B | $2.69B | $3.11B |
| Current liabilities | $437.79M | $417.84M | $422.23M | $277.52M | $315.72M |
| Total liabilities | $595.81M | $623.03M | $607.58M | $438.53M | $501.45M |
| Shareholders' equity | $2.62B | $2.48B | $2.36B | $2.25B | $2.60B |
| Cash flow statement | |||||
| Operating cash flow | $472.20M | $327.25M | $367.08M | $318.58M | $447.75M |
| Capital expenditure | $36.35M | $30.01M | $30.34M | $47.93M | $54.45M |
| Free cash flow | $435.85M | $297.25M | $336.74M | $270.65M | $393.30M |
| Investing cash flow | -$10.59M | -$286.29M | $54.21M | -$295.94M | -$44.91M |
| Financing cash flow | -$247.24M | -$287.81M | -$236.81M | -$610.56M | -$252.51M |
| Depreciation & amortization | $87.83M | $75.56M | $82.56M | $88.46M | $95.86M |
| Stock-based compensation | $128.51M | $119.83M | $118.49M | $114.92M | $99.70M |
| Dividends paid | $126.60M | $114.58M | $103.41M | $100.07M | $89.17M |
| Share buybacks | $124.99M | $160.00M | $149.28M | $530.49M | $245.86M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· Financial companies (banks, insurers, …) usually do not report gross profit or operating income; bank revenue is net revenue (net interest income + noninterest income), smaller than "gross interest income + noninterest income".
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.